The Illumina-backed microbial technology producer will list on the Nasdaq Capital Market through the reverse takeover transaction.

MIT spinout Ginkgo Bioworks will go public through a reverse merger with Soaring Eagle Acquisition Corp to list on the Nasdaq Capital Market.

AbbVie subsidiary Allergan Aesthetics has agreed to acquire Soliton, which is commercialising a cellulite treatment based on research at University of Texas.

The venture fund, focused on companies out of MIT, Harvard and Rochester, has collected more than $191m on its way to a $325m target.

The genetic sequencing technology developer has filed to raise up to $100m, having secured nearly $150m from investors including Legend Capital in the past two years.

The Sinopharm-backed oncology drug developer has raised series D1 funding in a round led by China Structural Reform Fund Corporation.

Cambridge’s gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.

The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.

The Meituan Dianping, Tencent and Swiss Re-backed health insurance marketplace operator priced its offering at the top of its range.

Roche Venture Fund and Amgen will invest in the stem cell-transplant technology developer through a reverse merger transaction which will give it a $490m market capitalisation.